35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16)
TLD-1 is a novel liposomal doxorubicin formulation with a small hydrodynamic liposome diameter of 60 nm (90 nm for Caelyx) and a high lipid-to-drug ratio. We present the final results of SAKK 65/16, a phase 1 first-in-human study to define TLD-1’s safety, recommended phase 2 dose (RP2D), preliminary activity and pharmacokinetics (PK) in patients with advanced solid tumors.
Authors
- Simon Haefliger (ORCID: https://orcid.org/0000-0002-9721-3314)
- Martina Klose (ORCID: https://orcid.org/0000-0001-8190-3700)
- K. Eckhardt
- C. Sessa
- Michael Schwitter
- A. Stathis
- Robin Michelet (ORCID: https://orcid.org/0000-0002-5485-607X)
- Stefanie Hayoz (ORCID: https://orcid.org/0000-0002-2265-6559)
- M. Joerger
- I. Colombo
- Manuela Rabaglio (ORCID: https://orcid.org/0000-0002-6764-1844)
- Sara Bastian (ORCID: https://orcid.org/0000-0003-2848-9162)
- D. Hess
- Stéfan Halbherr (ORCID: https://orcid.org/0009-0007-3641-6795)
- Charlotte Kloft (ORCID: https://orcid.org/0000-0001-9344-8514)
- K-L. Koster
- Anne Laughlin
- Katrin Gobat
Institutions
- Bern University of Applied Sciences (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Bern (CH)
- Ospedale San Giovanni Bellinzona (CH)
- Luzerner Kantonsspital (CH)
- Ospedale Regionale di Bellinzona e Valli (CH)
- Swiss Group For Clinical Cancer Research (CH)
- Kantonsspital Graubünden (CH)
- Freie Universität Berlin (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104193
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36